Newsroom

One of the Largest Studies on Preterm Birth Finds a Maternal Biomarker Test Significantly Reduces Neonatal Morbidities and Improves Neonatal Outcomes

Sera announced that it plans to host a virtual R&D day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m. PT.

Sera Prognostics announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference

Sera Prognostics announced that the results of the PRIME study were accepted as a late-breaking abstract for oral podium presentation at SMFM

Sera Prognostics will present at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024

Sera announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Sera announced financial results for the third quarter of 2024 ended September 30, 2024.

Sera announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6, 2024

Sera announced that the company will present at the H.C. Wainwright Global Investment Conference on Wednesday, September 11, 2024 at 10:00 a.m. ET

Zhenya Lindgardt, will participate in a panel discussion: Future of Genetic Testing – Babies and Beyond, on August 14 at 8:00 a.m. Pacific Time/11:00 a.m. Eastern Time.